Year archive

3D Medicines Inc. — 2026 filings

All 13 regulatory filings released by 3D Medicines Inc. (1244) in 2026, sourced directly from the official regulator.

13 Filings

2026 Period

2026 filings (13)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT EARLY COMPLETION OF ENROLLMENT IN THE PHASE III CLINICAL TRIAL OF ENVAFOLIMAB FOR NEOADJUVANT/ADJUVANT TREATMENT OF NON-SMALL CELL LUNG CANCER Regulatory Filings	2026-05-21	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 Regulatory Filings	2026-05-06	English
Annual Report 2025 Regulatory Filings	2026-04-30	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 Regulatory Filings	2026-04-02	English
DISCLOSEABLE TRANSACTION; AND CLARIFICATION ANNOUNCEMENT ON THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 Capital/Financing Update	2026-04-01	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 Earnings Release FY 2025	2026-03-31	English
DATE OF BOARD MEETING Report Publication Announcement	2026-03-19	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 Regulatory Filings	2026-03-04	English
VOLUNTARY ANNOUNCEMENT ENVAFOLIMAB SUPPLEMENTAL APPLICATION FOR CONDITIONAL-TO-REGULAR APPROVAL TRANSITION ACCEPTED BY NMPA Regulatory Filings	2026-02-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 Share Issue/Capital Change	2026-02-04	English
CHANGE OF CHIEF FINANCIAL OFFICER Board/Management Information	2026-01-12	English
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR FIRST-LINE TREATMENT OF BILIARY TRACT CANCER OF ENVAFOLIMAB ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2026-01-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 Share Issue/Capital Change	2026-01-06	English